Novartis Ag (NVS) Income towards Parent Company (2009 - 2025)

Novartis Ag (NVS) posted Income towards Parent Company of $42.0 billion for Q2 2025, down 4.68% sequentially from $44.0 billion in Q4 2024, and up 0.6% YoY from $41.7 billion in Q2 2024.

Novartis Ag (NVS) Income towards Parent Company (2009 - 2025) Analysis & Trends

Novartis Ag (NVS) has 15 years of Income towards Parent Company data on file, last reported at $42.0 billion in Q2 2025.

  • Quarterly Income towards Parent Company rose 0.6% year-over-year to $42.0 billion in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $42.0 billion (up 0.6% YoY) and the FY2025 annual result came in at $14.0 billion, down 68.25% from the prior year.
  • Income towards Parent Company slipped to $42.0 billion in Q2 2025 per NVS's latest filing, from $44.0 billion in the prior quarter.
  • The five-year high for Income towards Parent Company was $34001.4 billion in Q1 2022, with the low at $144.0 million in Q1 2023.
  • Average Income towards Parent Company over 5 years is $2298.3 billion, with a median of $44.0 billion recorded in 2024.
  • Year-over-year, Income towards Parent Company surged 2569920.56% in 2022 and slumped 100.0% in 2023.
  • Novartis Ag's Income towards Parent Company stood at $67.7 billion in 2021, then decreased by 12.29% to $59.3 billion in 2022, then decreased by 21.36% to $46.7 billion in 2023, then declined by 5.62% to $44.0 billion in 2024, then declined by 4.68% to $42.0 billion in 2025.
  • Business Quant data shows NVS's Income towards Parent Company at $42.0 billion in Q2 2025, $44.0 billion in Q4 2024, and $41.7 billion in Q2 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn

Historic Data

Download Data
DateValue
Jun 30, 2025 41.99 Bn
Dec 31, 2024 44.05 Bn
Jun 30, 2024 41.73 Bn
Dec 31, 2023 46.67 Bn
Sep 30, 2023 250.00 Mn
Jun 30, 2023 51.85 Bn
Mar 31, 2023 144.00 Mn
Dec 31, 2022 59.34 Bn
Sep 30, 2022 245.00 Mn
Jun 30, 2022 62.93 Bn
Dec 31, 2021 67.66 Bn
Sep 30, 2021 1.40 Bn
Jun 30, 2021 54.04 Bn
Mar 31, 2021 14,001.31 Bn
Dec 31, 2020 56.60 Bn
Sep 30, 2020 1.41 Bn
Jun 30, 2020 53.81 Bn
Mar 31, 2020 194.00 Mn
Dec 31, 2019 55.47 Bn
Jun 30, 2019 51.43 Bn